Literature DB >> 32816185

Cancer stem cell generation during epithelial-mesenchymal transition is temporally gated by intrinsic circadian clocks.

Arpan De1,2, Dilshan H Beligala1,3, Vishal P Sharma1,4, Christian A Burgos1, Angelia M Lee1, Michael E Geusz5.   

Abstract

Epithelial-mesenchymal transition (EMT) is a key event preceding tumor cell metastasis that increases cell invasiveness and cancer stem cell (CSC) populations. Studies suggest that genes used in generating circadian rhythms also serve in regulating EMT. To test the role of circadian clocks in cellular EMT events two cancer cell lines were compared, one that has a well-established circadian clock, C6 from rat glioma, and one that does not, MCF-7 from human breast tumor. MCF-7 tumorsphere cultures were tested for evidence of circadian rhythms because of previously reported circadian rhythm enhancement in C6 tumorspheres shown by elevated rhythm amplitude and increased expression of circadian clock gene Per2. Bioluminescence imaging of Per2 gene expression in MCF-7 tumorspheres revealed a previously unconfirmed circadian clock in this important cancer research model. Inducing CSC generation through EMT in C6 and MCF-7 monolayer cultures revealed circadian oscillations in the size of the post-EMT CSC population, confirming that circadian rhythms are additional processes controlling this stage of cancer progression. EMT was verified by distinct cellular morphological changes and expression of stem cell proteins OCT4, nestin, MSI1, and CD133 along with EMT-related proteins ZEB1, vimentin, and TWIST. Quantifying single-cell events and behaviors through time-lapse imaging indicated the post-EMT population size was determined largely by circadian rhythms in epithelial-like cancer cells undergoing EMT. We then identified a specific phase of the circadian rhythm in Per2 gene activation as a potential target for therapeutic treatments that may suppress EMT, minimize CSCs, and limit metastasis.

Entities:  

Keywords:  Cancer stem cell; Circadian rhythm; Epithelial-mesenchymal transition; OCT4; Tumorsphere

Mesh:

Substances:

Year:  2020        PMID: 32816185     DOI: 10.1007/s10585-020-10051-1

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  6 in total

1.  The Relevance of Circadian Clocks to Stem Cell Differentiation and Cancer Progression.

Authors:  Astha Malik; Shreya Nalluri; Arpan De; Dilshan Beligala; Michael E Geusz
Journal:  NeuroSci       Date:  2022-03-29

2.  Stress-induced epinephrine promotes epithelial-to-mesenchymal transition and stemness of CRC through the CEBPB/TRIM2/P53 axis.

Authors:  Zili Zhou; Yan Shu; Haijun Bao; Shengbo Han; Zhengyi Liu; Ning Zhao; Wenzheng Yuan; Chenxing Jian; Xiaogang Shu
Journal:  J Transl Med       Date:  2022-06-07       Impact factor: 8.440

Review 3.  The role of the circadian clock in cancer hallmark acquisition and immune-based cancer therapeutics.

Authors:  Elizabeth Cash; Sandra Sephton; Cassandra Woolley; Attia M Elbehi; Anu R I; Bene Ekine-Afolabi; Victor C Kok
Journal:  J Exp Clin Cancer Res       Date:  2021-04-01

4.  The Circadian Gene NPAS2 Act as a Putative Tumor Stimulative Factor for Uterine Corpus Endometrial Carcinoma.

Authors:  Xiaojiao Zheng; Xiuyi Lv; Linyan Zhu; Kejun Xu; Cong Shi; Lining Cui; Huiqing Ding
Journal:  Cancer Manag Res       Date:  2021-12-22       Impact factor: 3.989

Review 5.  Exploring glioblastoma stem cell heterogeneity: Immune microenvironment modulation and therapeutic opportunities.

Authors:  Amanda L Johnson; John Laterra; Hernando Lopez-Bertoni
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738

6.  BMAL1 Knockdown Leans Epithelial-Mesenchymal Balance toward Epithelial Properties and Decreases the Chemoresistance of Colon Carcinoma Cells.

Authors:  Yuan Zhang; Aurore Devocelle; Christophe Desterke; Lucas Eduardo Botelho de Souza; Éva Hadadi; Hervé Acloque; Adlen Foudi; Yao Xiang; Annabelle Ballesta; Yunhua Chang; Julien Giron-Michel
Journal:  Int J Mol Sci       Date:  2021-05-16       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.